
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer
The Institute of Cancer Research, London, UK, has welcomed the announcement by NICE that it…
The Institute of Cancer Research, London, UK, has welcomed the announcement by NICE that it…
An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of…
The Institute of Cancer Research, London, UK, has launched a major fundraising appeal as it…
The Oncology Podcast, brought to you by www.oncologynews.com.au, is proud to present the next episode…
The Institute of Cancer Research, London, has expressed disappointment at the decision by NICE not to recommend…
A genetic anomaly in certain men with prostate cancer may impact their response to common…
In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response…
A new blood test could predict which men with advanced prostate cancer will respond to…
A combination of two drugs for prostate cancer is safe and shows signs of effectiveness…
Universities should work with new forms of commercial partner to take their own cancer drugs…